How CARsgen’s EHA 2026 data could change investor debate around allogeneic CAR T
Find out how CARsgen’s CT0596 and CT1190B data could reshape the allogeneic CAR T race in cancer therapy.
Pharma & Biotech
Pharma & Biotech
What CARsgen Therapeutics’ RMB370m manufacturing plan reveals about CAR-T execution risk
CARsgen Therapeutics is expanding CAR-T manufacturing in Shanghai as solid tumor programs near approval. Find out why this matters for scale and adoption.